Skip to content

A single-center, randomized, double-blind, controlled trial for Low-dose dopamine combined with tolvaptan in the treatment of cardiorenal syndrome

A single-center, randomized, double-blind controlled trial for Low-dose dopamine combined with tolvaptan in the treatment of cardiorenal syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035485
Enrollment
Unknown
Registered
2020-08-12
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiorenal Syndrome

Interventions

dopamine:low-dose dopamine
dopamine and tolvaptan:low-dose dopamine and tolvaptan
contol: base treament

Sponsors

Xinhua Hospital Affliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years old males and females; 2. Symptoms meeting the diagnostic criteria for CHF plus a history of CHF>=3 months or clinical symptoms of heart failure>=months; 3. NYHA cardiac function classification II through IV (hemodynamically stable); 4. Serum NT-proBNP >=450 pg/ml; 5. Any other reason leading to eGFR decrease (=3 months; 6. Voluntary participation in this study and understanding and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Simultaneous merger of primary diseases such as liver function, blood system, and endocrine system, tumor patients, severe neuroendocrine system diseases and psychotic patients; 2. Patients with valvular heart disease with left ventricular outflow tract obstruction, myocarditis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, large aneurysm, arterial dissection, congenital heart disease, and unobvious hemodynamic changes; 3. pregnant or preparing pregnant and lactating women; 4. allergic persons, or those known to be allergic to treatment drugs; 5. Participate in other drug clinical investigators within 1 month; 6. used any other Chinese patent medicine that could impair cardiorenal functions for previous 3 months; 7. According to the investigator's judgment, the patient cannot complete this study or cannot comply with the requirements of this study.

Design outcomes

Primary

MeasureTime frame
NT-proBNP and Glomerular filtration rate;

Secondary

MeasureTime frame
Blood creatinine, blood urea nitrogen, indoxyl-sulfate, cardiac uhrasonography;

Countries

China

Contacts

Public ContactZhang Song

Shanghai Jiao Tong University School of Medicine

zhs16888@hotmail.com+86 13916013975

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026